Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China flag China · Delayed Price · Currency is CNY
24.53
-1.02 (-3.99%)
Aug 21, 2026, 3:04 PM CST

SHE:300255 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-355.81-357.9-249.48-1,24017.51233.57
Depreciation & Amortization
69.5569.5573.774.756.9455.8
Other Amortization
2.212.211.050.80.62-
Loss (Gain) From Sale of Assets
0.230.230.7800.01-
Asset Writedown & Restructuring Costs
3.683.681.31.782.120.11
Loss (Gain) From Sale of Investments
-1.67-1.67-33.26-0.01--
Provision & Write-off of Bad Debts
29.5329.536.6115.386.51-0.13
Other Operating Activities
133.79218.66169.76730.5698.162.96
Change in Accounts Receivable
12.2912.29-21.01284.66-97.0691.52
Change in Inventory
44.3644.36190161.28-156.01-398.02
Change in Accounts Payable
32.3232.32-82.2513.8272.17-48.54
Operating Cash Flow
-27.155.6856.2233.733.132.87
Operating Cash Flow Growth
--0.95%66.69%979.06%8.85%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-123.85-123.36-239.59-239.32-431.22-308.08
Sale of Property, Plant & Equipment
--0.060.020-
Investment in Securities
---0--
Other Investing Activities
0.2-05.770.45-0.10.78
Investing Cash Flow
-123.6-123.31-233.76-238.85-431.32-307.31

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-2,2012,0001,3462,8161,581
Total Debt Issued
2,7822,2012,0001,3462,8161,581
Long-Term Debt Repaid
--2,242-1,687-1,529-2,030-1,182
Total Debt Repaid
-2,700-2,242-1,687-1,529-2,030-1,182
Net Debt Issued (Repaid)
82.22-41.31312.96-182.36786.08399.46
Common Dividends Paid
-118-118.69-119.93-107.73-124-61.89
Other Financing Activities
74.45101.46-11.3-4.85-8.635.39
Financing Cash Flow
38.66-58.54181.73-294.94653.44342.96

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
0.382.280.843.0312.96-3.49
Net Cash Flow
-111.66-123.895.03-497.03238.235.04

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-150.95-67.68-183.37-205.6-428.1-305.21
Free Cash Flow Growth
------
Free Cash Flow Margin
-17.30%-7.73%-17.79%-14.58%-18.32%-10.28%
Free Cash Flow Per Share
-0.17-0.07-0.20-0.22-0.49-0.33
Levered Free Cash Flow
-10.8482.38-43.8855.71-500.03-469.98
Unlevered Free Cash Flow
50.04142.9520.39115.97-441.88-431.04

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
33.4728.9822.83149.8370.81163.73
Change in Working Capital
91.3991.3985.78450.73-178.69-349.44